- Histology-Agnostic Biomarkers in GI Malignancies
- Biomarker-Driven Treatment of Advanced Colorectal Cancer
- Biomarker-Driven Treatment of Pancreatic and Hepatobiliary Cancer
- Biomarker-Driven Treatment: Gastric, Esophageal, and Gastroesophageal Junction Cancers
- Live Audience Question and Answer Session
Date / Time
Sheraton Grand Chicago
John L. Marshall, MD
Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Michael Pishvaian, MD, PhD
Department of Gastrointestinal Medical Oncology
Co-director for Clinical Research
Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research
The University of Texas MD Anderson Cancer Center
Manish A. Shah, MD
Bartlett Family Professor of Gastrointestinal Oncology
Chief, Solid Tumor Services
Director, Gastrointestinal Oncology Program
Co-Director, Center for Advanced Digestive Care
Weill Cornell Medical College
New York, New York
The goal of this program is to improve the knowledge and competence of learners in biomarker testing to guide selection of individualized treatments for patients with gastrointestinal malignancies.
This educational program is intended for medical oncologists and other healthcare professionals who treat patients with gastrointestinal malignancies.
Upon completion of this activity, participants should be able to:
- Apply the available data and expert recommendations for molecular profiling in GI malignancies to guide treatment selection
- Plan individualized therapeutic strategies for patients with GI malignancies based on predictive biomarker assessment
- Counsel patients on tumor molecular profile and how this information will guide therapy decisions to optimize outcomes and quality of life
- Appraise ongoing clinical trials for novel biomarker-driven treatment strategies in GI malignancies for patient counsel and potential enrollment
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.